Life Sciences 2026: Trends and challenges

The Life Sciences Morning event (La Matinale des Sciences de la Vie) referred to here as ‘La Matinale’ held on 4 June 2026, brought together industry and legal experts to discuss the rapidly evolving landscape of health and insurance. The session highlighted how current legal debates, regulatory reforms, and international pressures are reshaping risk management and business strategy for life sciences companies and their insurers.

Anxiety damages: A persistent legal debate

The recognition of “préjudice d’anxiété” (anxiety damages) remains a central topic in French and European legal circles. Recent French Supreme Court decisions have confirmed that individuals exposed to a high risk of developing serious illness can claim for anxiety, even without physical symptoms (French civil supreme court,1st civil chamber, 18 February 2026, n°21-23.415). Recently, the French Supreme Court (Mixt chamber, 29 May 2026, n° 24-17.384) confirmed that anxiety damages resulting from exposure to a toxic or harmful substance, presenting a high risk of developing a serious pathology, are considered a consequence of bodily injury.

This presumption of anxiety damage is not only a game changer for claimants, but also a source of ongoing legal discussion for businesses and insurers. The issue is far from settled, as courts continue to refine the criteria for compensation and the evidentiary requirements.

Product liability: a dynamic and internationally influenced landscape

The question of liability for defective products is more relevant than ever for life sciences companies and their insurers. The sector is witnessing ongoing legal debates about the scope and nature of product liability, particularly as products become more complex, digitalised and interconnected.

A concrete example from La Matinale is the CJUE decision of 26 March 2026 (C-338/24, LF c. Sanofi Pasteur), where the Court of Justice of the European Union confirmed that a victim can pursue both a claim under the EU directive on defective products and a separate claim based on general liability for wrongful conduct, even if both actions concern the same situation. The Court also clarified that the three-year limitation period begins when the claimant is aware of the damage, the defect and the identity of the producer, rather than from the date of medical consolidation.

Internationally, the rise of “nuclear verdicts” in the United States - jury awards exceeding $10 million, often in product liability cases involving pharmaceuticals, medical devices, and consumer health products - has sent shockwaves through the industry. For instance, in 2024, there were 135 nuclear verdicts in the US, including a $495 million award against Abbott (Similac). These verdicts reflect shifting social attitudes, aggressive litigation funding, and a growing mistrust of large corporations. The ripple effects are felt internationally, as European companies face increasing cross-border litigation and regulatory convergence.

For manufacturers, distributors, and insurers, this means that compliance, documentation, and risk transfer strategies must be more robust and forward-looking than ever. La Matinale discussions underscored the importance of monitoring international litigation trends, adapting insurance policies, and ensuring that contractual arrangements are clear and comprehensive. In this context, product liability is not just a legal issue: it is a strategic concern that requires constant vigilance and adaptation.

Supply chain: managing regulatory and geopolitical pressures

Supply chain management in life sciences has never been more challenging. The sector is grappling with constrained capacity, regulatory bottlenecks, and geopolitical tensions, all while demand and complexity are soaring. The new EU pharmaceutical and medical device regulations impose stricter obligations on supply continuity, shortage prevention, and transparency. Companies must now anticipate and manage risks related to production, distribution, and compliance, with the threat of administrative sanctions and litigation for non-compliance.

La Matinale highlighted how these pressures are unfolding in a global context, with disruptions in one region causing cascading effects worldwide. Regulatory requirements are increasingly harmonised across borders and the need for robust, agile, and compliant supply chains is now a strategic imperative. The environment is not only increasingly constrained and complex, but also expanding, as companies pursue new markets and partnerships while navigating regulatory and operational risks. The discussions at La Matinale focused on practical solutions, including contractual safeguards, insurance adaptations, and collaborative approaches to risk management.

PFAS and environmental liability: regulatory scrutiny and insurance challenges

PFAS (“forever chemicals”) are under intense regulatory and legal scrutiny, with the EU moving towards broad restrictions and high-profile litigation emerging in both Europe and the US. These substances, known for their longevity and bioaccumulation, pose significant health and environmental risks. Insurers are responding with new exclusions and sub-limits, making it essential for companies to understand and manage their PFAS exposure.

The technical and regulatory hurdles for substituting PFAS in medical products are considerable, and the risk of litigation for environmental and health damages is rising. La Matinale underscored the importance of mapping PFAS exposures, updating risk management programmes, and monitoring regulatory developments to anticipate compliance and product reformulation needs. The issue is not only a regulatory challenge but also a business risk, with implications for product design, supply chain management, and insurance coverage.

Conclusion: navigating uncertainty and seizing opportunities

The legal and regulatory environment for life sciences and insurance is evolving, but with the right strategy, organisations can transform uncertainty into a source of competitive advantage. The ongoing debates around anxiety damages and product liability, the imminent EU reform, the international context of high-value litigation, and the challenges of supply chain and environmental risk all demand proactive engagement and robust risk management. La Matinale provided a platform for reflection, encouraging companies to anticipate changes, adapt their practices, and collaborate with partners and advisors to secure their future in a complex and developing global landscape.